Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02573896 · ClinicalTrials.gov registry record · Phase 1

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

A Phase 1 study of Neuroblastoma, sponsored by New Approaches to Neuroblastoma Therapy Consortium.

Active
Registry status
Phase 1
Development phase
13
Enrollment target
11
Study locations

NCT02573896 is a Phase 1 study of Neuroblastoma that is active but no longer recruiting, run by New Approaches to Neuroblastoma Therapy Consortium. The registered enrollment target is 13 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (95% lower). The trial reports 11 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02573896, a Phase 1 study of Neuroblastoma, is active but no longer recruiting, sponsored by New Approaches to Neuroblastoma Therapy Consortium.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
13 participants
Enrollment target
11
Study locations

Study Summary

This NANT trial will determine the maximum tolerated dose (MTD) of autologous expanded natural killer (NK) cells when combined with standard dosing of dinutuximab and will assess the feasibility of adding lenalidomide at the recommended Phase II dose of the expanded NK cells with dinutuximab, for treatment of children with refractory or recurrent neuroblastoma.

Conditions Studied

Neuroblastoma

Interventions

  • DRUG Lenalidomide
  • DRUG Dinutuximab
  • BIOLOGICAL NK Cells

Study Locations (11)

California

  • Children's Hospital Los Angeles - Los Angeles
  • UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati
  • Nationwide Children's Hospital - Columbus

Georgia

  • AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus - Atlanta

Illinois

  • University of Chicago Comer Children's Hospital - Chicago

Massachusetts

  • Childrens Hospital Boston, Dana-Farber Cancer Institute. - Boston

Michigan

  • C.S Mott Children's Hospital - Ann Arbor

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia

Texas

  • Cook Children's Healthcare System - Fort Worth

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2019-01-14
Est. Completion 2026-12
Phase Phase 1

Sponsor

New Approaches to Neuroblastoma Therapy Consortium

23 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02573896

The ClinicalTrials.gov registry entry for NCT02573896 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (95% lower). The listed sponsor is New Approaches to Neuroblastoma Therapy Consortium, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 3 interventions - of which Lenalidomide is the first listed.

NCT02573896 reports 11 study locations spanning 9 distinct geographic areas - top geographies include California, Ohio, Georgia.

Frequently Asked Questions

What is clinical trial NCT02573896 about?

NCT02573896 is a clinical study titled "Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells". This NANT trial will determine the maximum tolerated dose (MTD) of autologous expanded natural killer (NK) cells when combined with standard dosing of dinutuximab and will assess the feasibility of adding lenalidomide at the recommended Phase II dose of the expanded NK cells with dinutuximab, for tr...

What is the current status of trial NCT02573896?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2019-01-14. Estimated completion is 2026-12.

What conditions does trial NCT02573896 study?

This clinical trial studies the following conditions: Neuroblastoma.

What interventions are being tested in trial NCT02573896?

The interventions under investigation include: Lenalidomide (DRUG), Dinutuximab (DRUG), NK Cells (BIOLOGICAL).

Who is sponsoring clinical trial NCT02573896?

This trial is sponsored by New Approaches to Neuroblastoma Therapy Consortium, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02573896 being conducted?

This trial has 11 study locations across California, Georgia, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neuroblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neuroblastoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.